RARECast
A podcast by RARECast - Thursdays
Categories:
516 Episodes
-
What Rare Patient-Investors Can Learn From Venture Capitalists
Published: 7/26/2017 -
Novel Effort Delivers Failed DMD Drug to Former Clinical Trial Participants
Published: 7/19/2017 -
Centogene Seeks to Deliver Diagnoses to Rare Disease Patients Early
Published: 7/12/2017 -
Albireo Advances Pipeline for Rare Liver and Gastrointestinal Diseases
Published: 7/5/2017 -
aTyr Pharma Seeks to Modulate Activity in FSHD and Other Rare Disease
Published: 6/28/2017 -
Summit Pursues A Different Approach to Treating Duchenne
Published: 6/21/2017 -
Delivering Enzyme Replacement Therapies Across the Blood-Brain Barrier
Published: 6/14/2017 -
Sangamo Advances Gene Editing Therapies for Multiple Rare Diseases into the Clinic
Published: 6/7/2017 -
Navigating the Challenges of Rare Disease Drug Development
Published: 5/31/2017 -
Accelerating Rare Disease Drug Discovery
Published: 5/24/2017 -
Experimental Rare Disease Therapy Wins New FDA Reg Med Designation
Published: 5/17/2017 -
How Rare Disease Patients Can Get their Voices Heard in Drug Discovery and Development
Published: 5/10/2017 -
One Patient's Difficult Road to a Rare Diagnosis
Published: 5/3/2017 -
How Researchers Diagnosed Four Patients with a Never-Before-Identified Rare Disease in a Day
Published: 4/26/2017 -
Stem Cell Gene Therapy Restores Immune System in Kids with SCID
Published: 4/19/2017 -
Rare Disease Advocates Push for Incentives to Drugmakers Pulled from Cures Act
Published: 4/12/2017 -
Non-Profit Drug Company Seeks to Advance Rare Disease Therapies
Published: 4/5/2017 -
Innovative Collaboration Model Drives Treatment for Rare Disease
Published: 3/29/2017 -
Girl with Rare Disease Inspires Search for Bone Marrow Donors
Published: 3/22/2017 -
A Quest for Tribe: Searching for Others with the Same Ultra-Rare Mutation
Published: 3/15/2017
RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.